SCHEMBL23054846

SCHEMBL23054846

Nc1ccc(NC(=O)CCCCCCC(=O)NO)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 17/20 0.71
HDAC6 Q9UBN7 17/20 0.71
HDAC2 Q92769 16/20 0.71
HDAC3 O15379 15/20 0.71
HDAC11 Q96DB2 13/20 0.71
HDAC8 Q9BY41 13/20 0.71
HDAC10 Q969S8 13/20 0.71
NCOR2 Q9Y618 3/20 0.71
HDAC4 P56524 12/20 0.70
HDAC7 Q8WUI4 12/20 0.70
HDAC9 Q9UKV0 12/20 0.70
HDAC5 Q9UQL6 12/20 0.70
KDM4E B2RXH2 1/20 0.70
BRD4 O60885 1/20 0.70
NCOR1 O75376 1/20 0.70
NR1I2 O75469 1/20 0.70
EGFR P00533 1/20 0.70
CYP3A4 P08684 1/20 0.70
LTA4H P09960 1/20 0.70
NR0B1 P51843 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31473065 0.93 HDAC1 (0.63) HDAC1HDAC6HDAC2HDAC3HDAC11
SCHEMBL18660183 0.93 HDAC1 (0.63) HDAC1HDAC6HDAC2HDAC3HDAC11
SCHEMBL18660182 0.91 MEN1 (0.62) HDAC1HDAC6HDAC2HDAC3HDAC11
SCHEMBL31635263 0.91 HDAC1 (0.83) HDAC1HDAC6HDAC2HDAC3HDAC11
SCHEMBL8244867 0.86 HDAC1 (0.74) HDAC1HDAC6HDAC2HDAC3HDAC11
SCHEMBL1064492 0.86 HDAC1 (0.74) HDAC1HDAC6HDAC2HDAC3HDAC11
SCHEMBL3918802 0.85 CA1 (0.66) HDAC1HDAC2HDAC3
SCHEMBL7774872 0.85 CA1 (0.66) HDAC1HDAC2HDAC3
SCHEMBL7770155 0.85 CA1 (0.66) HDAC1HDAC2HDAC3
SCHEMBL3913717 0.85 CA1 (0.66) HDAC1HDAC2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970107-B1 PHOTOSWITCHABLE HDAC INHIBITORS MASSACHUSETTS GEN HOSPITAL (US) 2023-11-15 EP disclosed
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC6 10/4885HDAC2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.